Sickle Cell Disease Treatment Market
Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, by Type (Medication (Hydroxyurea, L-Glutamine Oral Powder, Crizanlizumab, Voxelotor, Pain-relieving Medication, and others), Blood Transfusions and Bone-Marrow Transplant), by Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta-Thalassemia, and Sickle Beta-Zero Thalassemia), and Forecast 2019-2025 Update Available - Forecast 2024-2030
The global sickle cell disease treatment market is estimated to grow at a CAGR of around 7% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of sickle cell disease and growing development in the life science industry. For instance, in November 2019, FDA approved the use of crizanlizumab-tmca for sickle cell disease treatment with the aim to reduce the frequency of vaso-occlusive crises (VOCs) in adults. In November 2019, the FDA granted approval to Voxelotor for sickle cell disease patients in adults.
The sickle cell disease treatment has majorly three factors including relieving the vaso-occlusive crisis, reducing inflammation and stimulating HbF production. The potential treatment of sickle cell disease includes a therapy combining the Rho-kinase inhibitor Hydroxyfasudil and Hbf inducers. It works similarly as hydroxyurea in order to reduce inflammation and relieving of pain from the vaso-occlusive crisis. It is already approved for the treatment of pulmonary hypertension hence it is efficient too.
Segmentation
The global sickle cell disease treatment market is segmented based on type and disease type. Based on drug type, the market is classified into medication, blood transfusions and a bone-marrow transplant. Based on disease type, the market is classified into sickle cell anemia, sickle hemoglobin c disease, sickle beta-thalassemia and sickle beta-zero thalassemia. Technological innovation in the healthcare industry and the vast geographical presence of sickle cell disease patients is expected to contribute to the growth of the market.
Regional Outlook
Geographically, the global sickle cell disease treatment market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is estimated to witness significant growth in the market owing to the significant prevalence of the geriatric population and rising incidences of sickle cell diseases are primarily encouraging the market growth in the region. Increasing healthcare expenditure and the increasing number of multi-specialty hospitals is further strengthening the market growth in the region. Moreover, the major companies are expanding their presence in this region, which in turn, will likely contribute to the significant growth of the sickle cell disease treatment market in the region.
Global Sickle Cell Disease Treatment Market Growth, by Region 2019-2025
North America has witnessed potential growth in the market
North America has attracted a considerable share in the market owing to the presence of major companies, such as Pfizer, Inc., Bristol-Myers Squibb Co., Novartis AG and Eli Lilly and Co. in the region. These companies are significantly focusing on marketing their products across the globe and gain a competitive advantage. Additionally, wide-ranging treatment options offered by these companies are supporting to attract a significant number of distribution channels, which in turn, is contributing to the considerable revenue generation from North America. Additionally, significant growth in the FDA approvals for sickle cell disease treatment in the region is further strengthening the growth of the market.
Competitive Landscape
The major companies providing sickle cell disease treatment include Emmaus Life Science, Inc., Bristol-Myers Squibb Co., Pfizer, Inc., Global Blood Therapeutics, Inc., and Novartis AG. These companies have captured major market share and continuously making efforts to expand their market share. For instance, in 2019, AstraZeneca launched sickle cell disease medicine under brand name Brilinta in the US and Brilique in the rest of the world with the FDA approved Ticagrelor compound containing into it. Ticagrelor is a blood thinner used to prevent blood platelet clumping benefitting the sickle cell disease treatment patient in reducing blood vessel blockages.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global sickle cell disease treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Emmaus Life Science, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Bristol-Myers Squibb Co.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Global Blood Therapeutics, Inc
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Sickle Cell Disease Treatment Market by Type
5.1.1. Medication
5.1.1.1. Hydroxyurea
5.1.1.2. L-Glutamine Oral Powder
5.1.1.3. Crizanlizumab
5.1.1.4. Pain-Relieving Medications
5.1.1.5. Voxelotor
5.1.2. Blood Transfusions
5.1.3. Bone-Marrow Transplant
5.2. Global Sickle Cell Disease Market by Disease Type
5.2.1. Sickle Cell Anemia
5.2.2. Sickle Hemoglobin C Disease
5.2.3. Sickle Beta Thalassemia
5.2.4. Sickle Beta-Zero Thalassemia
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Acceleron Pharma, Inc.
7.2. Arena Pharmaceuticals, Inc.
7.3. AstraZeneca plc
7.4. Baxter International, Inc.
7.5. Blue bird bio, Inc.
7.6. Bristol-Myers Squibb Co.
7.7. Eli Lilly and Co.
7.8. Emmaus Life Science, Inc.
7.9. Global Blood Therapeutics, Inc.
7.10. Medunik USA, Inc.
7.11. Novartis AG
7.12. Pfizer, Inc.
7.13. Sangamo Therapeutics, Inc.
7.14. Sanofi S.A.
1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL BLOOD TRANSFUSIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL BONE-MARROW TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
6. GLOBAL SICKLE CELL ANEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL SICKLE HEMOGLOBIN C DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL SICKLE BETA THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL SICKLE BETA-ZERO THALASSEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
11. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
12. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
13. NORTH AMERICAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
14. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
15. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
16. EUROPEAN SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
17. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
20. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
21. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. US SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
6. UK SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
